Background: T-cell depletion (TCD) effectively reduces severe graft-versus-host dis-
| INTRODUCTION

T-cell depletion (TCD) is important for haploidentical donor (haplo)
hematopoietic cell transplantation (HCT) to reduce graft-versus-host disease (GVHD). TCD can be ex vivo in which T cells are removed from the allografts before infusion, or in vivo where anti-lymphocyte antibodies or immunosuppressive drugs such as high-dose cyclophosphamide are given to kill donor T cells after infusion. 1, 2 One early successful technique for haplo-HCT gave an anti-thymocyte globulin (ATG)-containing preparative regimen with immunomagnetic enrichment of CD34+ cells. 3 This indirectly depleted T cells and other donor immune cells extensively. The use of high-intensity conditioning, ATG, and megadose progenitor cells was able to overcome the high incidence of rejection previously seen. 3 However, the absence of adoptively transferred immune cells led to high risk of relapse and infection.
A recent strategy for providing more donor T cells in TCD haplo-HCT provided 1-2 × 10 6 haploidentical conventional T cells/kg recipient weight with donor regulatory T-cell co-infusion. 4 Using this approach, more robust donor T-cell reconstitution occurred with
CD4+ and CD8+ T cells reaching a count of 200/μL by approximately
Day +60 after transplantation. Selective TCD has also been used, such as immunomagnetic depletion of TCRαβ+ cells. [5] [6] [7] This method provides large doses of TCRγδ+ T cells, which may facilitate engraftment, protect against infection, and deliver some graft-versus-leukemia effect. [8] [9] [10] Novel methods have been developed to selectively deplete naive T cells and preserve memory T cells through CD45RA depletion.
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The alloreactivity of CD45RA− T-cell fraction seems to be less durable than that of CD45RA+ T cells. [15] [16] [17] Therefore, it is possible that large numbers of haploidentical donor CD45RA− T cells could be provided to the recipient without significantly increasing the risk of steroidrefractory acute GVHD and severe chronic GVHD. We have previously shown that the depletion of CD45RA+ cells provides robust early recovery of diverse memory T-cell populations in haplo-HCT utilizing a total lymphoid irradiation-based conditioning regimen without the need for serotherapy, such as ATG, alemtuzumab (Campath 1H), or muromonab-CD3 (OKT3). 18 We hypothesize that the observed memory T-cell reconstitution may confer protection against virulent viruses and more rapid lymphocyte reconstitution in the first 6 months after transplantation when compared with previous haplo-HCT strategies using non-selective TCD. Herein, we describe the results of 3 consecutive therapeutic haplo-HCT trials and compare the results from 2 trials that used broad CD3-depletion ex vivo and in vivo, vs the current trial that utilizes specific CD45RA-depletion without serotherapy.
| PATIENTS AND METHODS
| Patients and regimen
All patients who received initial allogeneic HCT on 3 consecu- 
| Virus surveillance
Quantitative PCR of blood samples for CMV, EBV, and adenovirus (ADV) was performed weekly until Day +100, then as indicated.
Viremia was defined as any PCR detection of the virus in the first 180 days post transplant. Duration was defined as time from first of 2 consecutive positive tests until the first of 2 consecutive negative tests for that virus, without subsequent consecutive positives in the next 6 weeks. Testing for ADV in the stool by qualitative PCR was performed when diarrhea was present. PCR for CMV was initially assayed as copy/mL whole blood, later the assay was changed to international units (IU)/mL plasma. Quality assurance testing demonstrated similar detection limits in both assays. The peak viral load was determined using the IU/mL assay in only 1 patient (CD45RAdep recipient with peak viral load at the detection limit, <2.14 log10 IU/mL). Similarly, EBV PCR was initially assayed as copy/μg DNA from blood mononuclear cells and later the assay was changed to IU/mL whole blood. Quality assurance testing again demonstrated similar detection limits. Thus, preemptive viral treatment strategies for these 3 viruses were not changed during the entire study period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . Preemptive treatment for CMV was initiated when a 1 log increase in viral load was detected.
Preemptive treatment for ADV was commenced for any detectible viral load in the blood, and was allowed at physician discretion for the presence of ADV in the stool based on the clinical perceived risk of dissemination.
| Immune monitoring
Blood was collected monthly for the first 6 months post transplant for CLIA-certified flow cytometric quantification of lymphocyte subsets in all recipients. Blood was collected in the 2 most recent trials from donors prior to mobilization and recipients at Day +100 and Day +180
for Vbeta spectratyping and T-cell receptor excision circles (TREC), as previously described. 
| Clinical outcome evaluations
Treatment-related mortality (TRM) was defined as any death not due to malignant progression. GVHD grading was performed according to standardized criteria. 20 Comprehensive audit of medical records and research data were performed by internal and extramural experts on all 31 patients on Trial 2 and all 26 patients on the current trial to verify the incidence of grade III-IV acute GVHD. The data presented here include any modifications to the research record following these audits.
| Statistical analysis
Two sample t tests or Wilcoxon Mann-Whitney tests were used to compare groups of CD3dep recipients and CD45RAdep recipients for continuous variables, depending on normality, while chi-square tests (Fisher's exact test for small samples) were used for categorical variables. Linear mixed models were conducted to examine the kinetics of immune reconstitution; the correlation structure and random effects
were chosen as the model with the lowest Akaike information criteria. Cumulative incidence rates for CMV reactivation were estimated using the Kalbfleisch-Prentice method with death as a competing risk and comparison using Gray's test. 21, 22 All analyses were for the first 180 days post transplantation. All reported P-values are 2-sided and T A B L E 1 (Continued) considered significant if <.05. SAS software version 9.4 (Cary, NC, USA) and GraphPad Prism version 6.07 (La Jolla, CA, USA) were used for statistical analyses and figure generation, respectively.
| RESULTS
| Patients
All 67 patients were under 21 years of age at the time of transplant. Cumulative cell doses of all donor grafts infused are detailed in 
| Viremia
Thirty-one (76%) CD3dep recipients had detectible viremia in the first 180 days post transplant, compared with 9 (35%) CD45RAdep recipients (P = .002; Figure 1A Adenovirus viremia was more frequent in CD3dep recipients-11 (27%) vs 1 (4%) (P = .02; Figure 1B) ; and the peak viral load was often higher ( Figure 2B ). In the lone CD45RAdep recipient with detectible ADV, the viral load was below the limit of quantification (2.0 log-10 copies/mL = 100 copies/mL). Nine of 11 (82%) CD3dep recipients with ADV were treated with cidofovir, and 4 (36%) also received DLI T-cell counts were 140/μL vs 0/μL, and median CD8+ T-cell counts were 315/μL vs 0/μL at Day +30 ( Figure 3A and 3B, respectively).
There was a paucity of B cells in both cohorts at Day +30, however quantitative B-cell recovery occurred earlier in CD45RAdep recipients, who had higher B-cell counts by Day +90 (P = .009; Figure 3C ).
NK-cell recovery was generally quantitatively normal to supra-normal
at Day +30 and remained normal throughout the first 6 months in both cohorts, but was quantitatively higher in CD3dep recipients despite the NK-cell graft provided to CD45RAdep recipients (P < .001).
The median TCR V-Beta total score was higher in CD45RAdep recipients at Day +100 (24 vs 107) (P < .001; Figure 4A ). TREC analysis showed very low quantities in both cohorts at Day +100 (median of 247 and 120 TREC/mL blood, respectively; Figure 4B ). 
| DISCUSSION
CD45RA-depleted allografts have few naive T cells but abundant memory T cells. Thus, we hypothesize that GVHD potential is reduced,
and that large memory-T-cell doses, which may facilitate engraftment without the need for serotherapy, can be given. Collectively, this novel approach may facilitate rapid immune reconstitution and prevent infection. We previously published a detailed analysis of early immune reconstitution in the first 17 CD45RAdep recipients and found that T-cell reconstitution was a direct recapitulation of the CD45RA- Because memory T cells retain potent virus-specific activity,
we hypothesized that recipients of CD45RA-depleted grafts and serotherapy-free conditioning would have better virus control. In line with this hypothesis, the incidence of viremia, the peak viral loads observed, and the duration of viremia were all substantially decreased when compared with CD3dep recipients. Importantly, memory T-cell recipients who developed viremia generally required less aggressive treatment.
Our data suggest that the newer CD45RA-depletion protocol may confer specific protection against adenoviral colitis and subsequent dissemination. CD3dep recipients developed adenoviral colitis more often and then also more frequently experienced dissemination to viremia than CD45RAdep recipients. The ADV outcome among
CD45RAdep recipients compared favorably to that of a recently published diverse allogeneic transplant population from our institution that had an incidence of adenoviral colitis of 33%, with 28% becoming viremic. 25 Additionally, protection against adenoviremia was present in CD45RAdep recipients despite reduced use of cidofovir in that cohort.
While the protective effect of CD45RA-depleted graft against ADV is evident, its effect against CMV viremia is unclear, because many CD45RAdep recipients received short-course GCV in the early post-transplant period despite the absence of CMV for preemptive treatment of HHV6 in the setting of fever and rash. Although the brief duration of preemptive HHV6 treatment (median only 14 days) was not likely fully protective against CMV reactivation (which typically required treatment through Day +100), 26 In summary, CD45RA depletion allows for the first time a large memory T-cell dose, which results in enhanced T-cell reconstitution as early as Day +30, protection from adenoviremia, and elimination of EBV prophylaxis. Critically, these benefits were achieved with no increase in the incidence of severe acute GVHD and a favorable early TRM in this high risk cohort which includes a large subset of patients with active refractory hematologic malignancy. Accrual to this therapeutic trial is ongoing to wholly assess important clinical outcomes such as full characterization of acute and chronic GVHD, disease control, hospital cost, and survival. Additional trials utilizing CD45RA-depletion in older patients and other disease groups will be needed to test the broad applicability of this selective T-cell depletion technique. 
